ARTICLE | Company News
ADC Therapeutics, BioAtla deal
July 15, 2013 7:00 AM UTC
BioAtla's VivaMab therapeutic development division granted ADC Therapeutics rights to VivaMab's VM101 for hematologic cancers. VivaMab will provide development support and is eligible to receive miles...